PLAT and androgen insensitivity syndrome: As a result of these findings, a first clinical trial to assess the safety and efficacy of DNase 1 in patients with AIS who received IV tPA and are eligible for EVT (NETs-TARGET study, ClinicalTrials.gov: NCT04785066) will be launched in the coming months.